A highly selective proteasome inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Epoxomicin

Item No. 10007806

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-threoninamide
CAS Number
134381-21-8
Synonyms
  • BU 4061T
Molecular Formula
C28H50N4O7
Formula Weight
554.7
Purity
≥95%
Formulation (Request formulation change)
A 250 µg/ml solution in DMSO
Solubility(Learn about Variance in Solubility)
DMSO: 10 mg/ml
SMILES
CC[C@H](C)[C@@H](NC(=O)[C@H]([C@@H](C)CC)N(C)C(=O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](CC(C)C)C(=O)[C@]1(C)OC1
InChi Code
InChI=1S/C28H50N4O7/c1-11-16(5)21(30-27(38)23(17(6)12-2)32(10)19(8)34)25(36)31-22(18(7)33)26(37)29-20(13-15(3)4)24(35)28(9)14-39-28/h15-18,20-23,33H,11-14H2,1-10H3,(H,29,37)(H,30,38)(H,31,36)/t16-,17-,18+,20-,21-,22-,23-,28+/m0/s1
InChi Key
DOGIDQKFVLKMLQ-JTHVHQAWSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    25 µg

    $70

    Add

    50 µg

    $129

    Add

    100 µg

    $242

    Add

    250 µg

    $535

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Epoxomicin is a potent anti-tumor agent isolated from Actinomycetes that is used as a selective and irreversible inhibitor of the 20S proteasome. It inhibits proteasome activity in cell growth assays with an IC50 value of 4 nM and demonstrates potent cytotoxicity against B16-F10, HCT116, and Moser solid tumor cells, as well as P388 and K562 leukemia cells with IC50 values ranging from 2-44 nM.1,2 By inhibiting osteoblast proteasome activity, epoxomicin stimulates bone formation at concentrations as low as 10 nM.3 Intraperitoneal injection of 1.5 mg/kg epoxomicin given daily for two weeks induces Parkinson’s-like symptoms in rats and addition of 100 nM epoxomicin to rat ventral midbrain cultures results in apoptosis specific to dopaminergic neurons.4,5 Epoxomicin-induced parkinsonism can be a useful model to examine mechanisms and therapies for the disease.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kim, K.B., Myung, J., Sin, N., et al. Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: Insights into specificity and potency. Bioorg. Med. Chem. Lett. 9(23), 3335-3340 (1999).

    2. Hanada, M., Sugawara, K., Kaneta, K., et al. Epoxomicin, a new antitumor agent of microbial origin. J. Antibiot. (Tokyo) 45(11), 1746-1752 (1992).

    3. Garrett, I.R., Chen, D., Gutierrez, G., et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J. Clin. Invest. 111(11), 1771-1782 (2003).

    4. McNaught, K.S.M., Perl, D.P., Brownell, A.L., et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann. Neurol. 56(1), 149-162 (2004).

    5. Rideout, H.J., Lang-Rollin, I.C.J., Savalle, M., et al. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J. Neurochem. 93(5), 1304-1313 (2005).

    Product Citations

    Njomen, E., Osmulski, P.A., Jones, C.L., et al. Small molecule modulation of proteasome assembly. Biochemistry 57(28), 4214-4224 (2018).